Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

ABSTRACT:

Background

Nicotinamide has been reported to protect against liver steatosis and metabolic imbalances in nonalcoholic fatty liver disease (NAFLD) in animal models.

Objectives

The objective was to investigate the efficacy and safety of nicotinamide supplementation in diabetic NAFLD patients.

Design

This is a prospective randomized controlled open label study.

Methods

Seventy diabetic NAFLD patients were randomly assigned either to the nicotinamide group (n = 35) who received nicotinamide 1000 mg once daily for 12 weeks in addition to their antidiabetic therapy or the control group (n = 35) who received their antidiabetic therapy only. The primary outcome was improvement in steatosis score, while secondary outcomes included assessment of liver stiff

SUBMITTER: El-Kady RR 

PROVIDER: S-EPMC8874180 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature